Nathaniel works in the research team, where the CAR T-cells are designed, and supports both the GMP team, where the CAR T-cells are manufactured, and the clinical team, who administer the CAR T-cells to participants in the trial. Read more here: First-car-t-cell-therapy-clinical-trialContinue Reading
The Australasian Myeloma Research Consortium (AMaRC) in collaboration with theAustralasian Leukaemia & Lymphoma Group (ALLG) and the Myeloma and Related DiseasesRegistry (MRDR) is conducting a phase II study to investigate the optimal usage oflenalidomide and/or bortezomib in newly-diagnosed transplant-ineligible myeloma patientsbased on a frailty score (frailty is characterised by a decline in body functions). If...Continue Reading
The New Zealand Myeloma Interest Group is comprised of representative haematologists from District Health Boards around the country with a special interest and expertise in MM. We reviewed the currently available evidence, including randomised controlled trials, retrospective data and conference abstracts, and interpreted these in the context of treatment options available in New Zealand to...Continue Reading
Myeloma experts convened in person and online for the 2022 Multiple Myeloma Queenstown Summit, hosted by Myeloma New Zealand. This year’s meeting included presentations from local and international experts, including the Chief Medical Officer of the International Myeloma Foundation, Professor Joseph Mikhael, Assistant Professor Jonathan Keats from Arizona, and Professor Simon Harrison and Dr Simon...Continue Reading
Myeloma New Zealand has started a campaign to press Pharmac into funding a treatment that has been standard-of-care throughout the Organisation for Economic Co-operation and Development (OECD) for more than five years. Myeloma NZ trustee Nichola Oakenfull has been interviewed for the article, well done Nichola! Here is the RNZ article: https://www.rnz.co.nz/news/national/474629/blood-cancer-patient-charity-campaigns-for-pharmac-to-fund-medicineContinue Reading
MEDIA RELEASE 7 September 2022 New Zealanders living with multiple myeloma, a deadly, relapsing/remitting blood cancer, are mounting a major, evidence-based campaign to press Pharmac into funding a transformative treatment that has been standard-of-care throughout the OECD for more than 5 years. Myeloma patient and trustee of Myeloma NZ Nichola Oakenfull says patients who’ve...Continue Reading
I hope that you are all keeping as well as possible with all these viruses circulating at the moment. I see from some comments on the Facebook page that some of you have used Paxlovid at the onset of Covid symptoms and found this intervention helpful. It is a challenging time for myeloma patients and...Continue Reading
OPINION: How long does it take you to make a decision about whether or not to buy something? You’ve got all the information in front of you. You know it’s a good product. It works. You need it. And you’ve got the money to buy it. So how long will it take? What if I said...Continue Reading
